Trial · NCT01839487
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Run-in Phase (Maximum Exposure:295 Days) | STARTED | Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 16 | |
| Run-in Phase (Maximum Exposure:295 Days) | STARTED | Run-in Phase - AG: Nab-paclitaxel + Gemcitabine | 7 | |
| Run-in Phase (Maximum Exposure:295 Days) | STARTED | Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | STARTED | Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | STARTED | Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | STARTED | Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | COMPLETED | Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | COMPLETED | Run-in Phase - AG: Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | COMPLETED | Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | COMPLETED | Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | COMPLETED | Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | COMPLETED | Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | NOT COMPLETED | Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 16 | |
| Run-in Phase (Maximum Exposure:295 Days) | NOT COMPLETED | Run-in Phase - AG: Nab-paclitaxel + Gemcitabine | 7 | |
| Run-in Phase (Maximum Exposure:295 Days) | NOT COMPLETED | Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | NOT COMPLETED | Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | NOT COMPLETED | Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 0 | |
| Run-in Phase (Maximum Exposure:295 Days) | NOT COMPLETED | Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine | 0 | |
| Phase 2 (Maximum Exposure:935 Days) | STARTED | Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 0 | |
| Phase 2 (Maximum Exposure:935 Days) | STARTED | Run-in Phase - AG: Nab-paclitaxel + Gemcitabine | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01839487/flow